Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Primary Biliary Cirrhosis Drug market report explains the definition, types, applications, major countries, and major players of the Primary Biliary Cirrhosis Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Enanta Pharmaceuticals Inc
Virobay Inc
NGM Biopharmaceuticals Inc
AlbireoPharma
GlaxoSmithKline Plc
CymaBay Therapeutics Inc
MediGene AG
Dr Falk Pharma GmbH
Johnson & Johnson
Intercept Pharmaceuticals Inc
By Type:
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others
By End-User:
Clinic
Hospital
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Primary Biliary Cirrhosis Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Primary Biliary Cirrhosis Drug Outlook to 2028- Original Forecasts
-
2.2 Primary Biliary Cirrhosis Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Primary Biliary Cirrhosis Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Primary Biliary Cirrhosis Drug Market- Recent Developments
-
6.1 Primary Biliary Cirrhosis Drug Market News and Developments
-
6.2 Primary Biliary Cirrhosis Drug Market Deals Landscape
7 Primary Biliary Cirrhosis Drug Raw Materials and Cost Structure Analysis
-
7.1 Primary Biliary Cirrhosis Drug Key Raw Materials
-
7.2 Primary Biliary Cirrhosis Drug Price Trend of Key Raw Materials
-
7.3 Primary Biliary Cirrhosis Drug Key Suppliers of Raw Materials
-
7.4 Primary Biliary Cirrhosis Drug Market Concentration Rate of Raw Materials
-
7.5 Primary Biliary Cirrhosis Drug Cost Structure Analysis
-
7.5.1 Primary Biliary Cirrhosis Drug Raw Materials Analysis
-
7.5.2 Primary Biliary Cirrhosis Drug Labor Cost Analysis
-
7.5.3 Primary Biliary Cirrhosis Drug Manufacturing Expenses Analysis
8 Global Primary Biliary Cirrhosis Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Primary Biliary Cirrhosis Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Primary Biliary Cirrhosis Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Primary Biliary Cirrhosis Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Primary Biliary Cirrhosis Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Budesonide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global FFP-104 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global GSK-2330672 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global MBX-8025 Consumption and Growth Rate (2017-2022)
-
9.1.5 Global NGM-282 Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Primary Biliary Cirrhosis Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Primary Biliary Cirrhosis Drug Market Analysis and Outlook till 2022
-
10.1 Global Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.2.2 Canada Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.2.3 Mexico Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.2 UK Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.3 Spain Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.4 Belgium Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.5 France Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.6 Italy Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.7 Denmark Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.8 Finland Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.9 Norway Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.10 Sweden Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.11 Poland Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.12 Russia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.3.13 Turkey Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.2 Japan Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.3 India Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.4 South Korea Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.5 Pakistan Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.7 Indonesia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.8 Thailand Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.9 Singapore Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.10 Malaysia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.11 Philippines Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.4.12 Vietnam Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.2 Colombia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.3 Chile Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.4 Argentina Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.5 Venezuela Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.6 Peru Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.5.8 Ecuador Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6.2 Kuwait Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6.3 Oman Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6.4 Qatar Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.7.2 South Africa Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.7.3 Egypt Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.7.4 Algeria Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Primary Biliary Cirrhosis Drug Consumption (2017-2022)
-
10.8.2 New Zealand Primary Biliary Cirrhosis Drug Consumption (2017-2022)
11 Global Primary Biliary Cirrhosis Drug Competitive Analysis
-
11.1 Enanta Pharmaceuticals Inc
-
11.1.1 Enanta Pharmaceuticals Inc Company Details
-
11.1.2 Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.1.4 Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Virobay Inc
-
11.2.1 Virobay Inc Company Details
-
11.2.2 Virobay Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Virobay Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.2.4 Virobay Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 NGM Biopharmaceuticals Inc
-
11.3.1 NGM Biopharmaceuticals Inc Company Details
-
11.3.2 NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.3.4 NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 AlbireoPharma
-
11.4.1 AlbireoPharma Company Details
-
11.4.2 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 AlbireoPharma Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.4.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 GlaxoSmithKline Plc
-
11.5.1 GlaxoSmithKline Plc Company Details
-
11.5.2 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 CymaBay Therapeutics Inc
-
11.6.1 CymaBay Therapeutics Inc Company Details
-
11.6.2 CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.6.4 CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 MediGene AG
-
11.7.1 MediGene AG Company Details
-
11.7.2 MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 MediGene AG Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.7.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Dr Falk Pharma GmbH
-
11.8.1 Dr Falk Pharma GmbH Company Details
-
11.8.2 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.8.4 Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Johnson & Johnson
-
11.9.1 Johnson & Johnson Company Details
-
11.9.2 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.9.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Intercept Pharmaceuticals Inc
-
11.10.1 Intercept Pharmaceuticals Inc Company Details
-
11.10.2 Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
11.10.4 Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Primary Biliary Cirrhosis Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Budesonide Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global FFP-104 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global GSK-2330672 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global MBX-8025 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global NGM-282 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Primary Biliary Cirrhosis Drug Market Analysis and Outlook to 2028
-
13.1 Global Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.5 France Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.3 India Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Primary Biliary Cirrhosis Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Primary Biliary Cirrhosis Drug
-
Figure of Primary Biliary Cirrhosis Drug Picture
-
Table Global Primary Biliary Cirrhosis Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Primary Biliary Cirrhosis Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Budesonide Consumption and Growth Rate (2017-2022)
-
Figure Global FFP-104 Consumption and Growth Rate (2017-2022)
-
Figure Global GSK-2330672 Consumption and Growth Rate (2017-2022)
-
Figure Global MBX-8025 Consumption and Growth Rate (2017-2022)
-
Figure Global NGM-282 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Table North America Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure United States Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure Germany Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure France Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure China Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure India Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table South America Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure Brazil Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure Bahrain Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure Nigeria Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Primary Biliary Cirrhosis Drug Consumption by Country (2017-2022)
-
Figure Australia Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Primary Biliary Cirrhosis Drug Consumption and Growth Rate (2017-2022)
-
Table Enanta Pharmaceuticals Inc Company Details
-
Table Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table Enanta Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
Table Virobay Inc Company Details
-
Table Virobay Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Virobay Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table Virobay Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
Table NGM Biopharmaceuticals Inc Company Details
-
Table NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table NGM Biopharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
Table AlbireoPharma Company Details
-
Table AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table AlbireoPharma Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
-
Table GlaxoSmithKline Plc Company Details
-
Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
-
Table CymaBay Therapeutics Inc Company Details
-
Table CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table CymaBay Therapeutics Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
Table MediGene AG Company Details
-
Table MediGene AG Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table MediGene AG Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
-
Table Dr Falk Pharma GmbH Company Details
-
Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table Dr Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
-
Table Johnson & Johnson Company Details
-
Table Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
-
Table Intercept Pharmaceuticals Inc Company Details
-
Table Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Main Business and Markets Served
-
Table Intercept Pharmaceuticals Inc Primary Biliary Cirrhosis Drug Product Portfolio
-
Figure Global Budesonide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global FFP-104 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global GSK-2330672 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global MBX-8025 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global NGM-282 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Table North America Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure China Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Primary Biliary Cirrhosis Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Primary Biliary Cirrhosis Drug Consumption Forecast and Growth Rate (2022-2028)
-
